”Financially, Race is well positioned, but we are keeping a close watch on capital allocation…”. That’s the big soften up. Delays in trials and formulations, new trial sites being opened, additional staff, international collaboration workshops, conferences, it all costs money. The only way this happens without another CR is if there is partnership with a big player… I’m not saying that can’t or won’t happen, just feels like they will have to shake the tim at least one more time given the perceived lack of progress.
what do you think was the new price sensitive news in the letter?
Ann: Letter to Shareholders, page-56
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |